|
1
|
Palmgren JS, Karavadia SS and Wakefield
MR: Unusual and underappreciated: small cell carcinoma of the
prostate. Semin Oncol. 34:22–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yao JL, Huang J and di Sant’Agnese PA:
Small cell carcinoma of the prostate. Diagn Histopathol.
14:117–121. 2008. View Article : Google Scholar
|
|
3
|
Haider K, Shahid RK, Finch D, et al: Extra
pulmonary small cell carcinoma: a Canadian province’s experience.
Cancer. 107:2262–2269. 2006.
|
|
4
|
Levenson RM Jr, Ihde DC, Matthews MJ,
Cohen MH, Gazdar AF, Bunn PA Jr and Minna JD: Small cell carcinoma
presenting as an extrapulmonary neoplasm: sites of origin and
response to chemotherapy. J Natl Cancer Inst. 67:607–612.
1981.PubMed/NCBI
|
|
5
|
Remic SC and Ruckdeschel JC:
Extrapulmonary and pulmonary small-cell carcinoma: tumor biology,
therapy, and outcome. Med Pediatr Oncol. 20:89–99. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanaka M, Suzuki Y, Takaoka K, Suzuki N,
Murakami S, Matsuzaki O and Shimazaki J: Progression of prostate
cancer to neuroendocrine cell tumor. Int J Urol. 8:431–436. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oesterling JE, Hauzeur CG and Farrow GM:
Small cell anaplastic carcinoma of the prostate: a clinical,
pathological and immunohistological study of 27 patients. J Urol.
147:804–807. 1992.PubMed/NCBI
|
|
8
|
Papandreou CN, Daliani DD, Thall PF, et
al: Result of a phase II study with doxorubicin, etoposide, and
cisplatin in patients with fully characterized small-cell carcinoma
of the prostate. J Clin Oncol. 20:3072–3080. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Sant’Agnese PA and Cockett AT: The
prostatic endocrine-paracrine (neuroendocrine) regulatory system
and neuroendocrine differentiation in prostatic carcinoma: a review
and future directions in basic research. J Urol. 152:1927–1931.
1994.
|
|
10
|
Deorah S, Rao MB, Raman R, Gaitonde K and
Donovan JF: Survival of patients with small cell carcinoma of the
prostate during 1973–2003: a population-based study. BJU Int.
109:824–830. 2012.
|
|
11
|
Spiess PE, Pettaway CA, Vakar-Lopez F, et
al: Treatment outcomes of small cell carcinoma of the prostate: a
single-center study. Cancer. 110:1729–1737. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao JL, Mardeb R and Bourne P: Small cell
carcinoma of the prostate: an immunohistochemical study. Am J Surg
Pathol. 30:705–712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755.
2011.
|
|
14
|
Uemura K, Nishihara K, Hayashi T, Tomiyasu
K and Matsuoka K: Improvement in urinary retention due to recurrent
anastomotic prostate cancer treated with various therapies by
intra-arterial infusion of cisplatin and ifosfamide. J Infect
Chemother. 18:753–755. 2012. View Article : Google Scholar
|
|
15
|
Früh M, Kacsir B, Ess S, Cerny T,
Rodriguez R and Plassnilm L: Extrapulmonary small cell carcinoma:
an indication for prophylactic cranial irradiation? A single center
experience. Strahlenther Onkol. 187:561–567. 2011.PubMed/NCBI
|
|
16
|
Walenkamp AM, Sonke GS and Sleijfer DT:
Clinical and therapeutic aspects of extrapulmonary small cell
carcinoma. Cancer Treat Rev. 35:228–236. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vashchenko N and Abrahamsson PA:
Neuroendocrine differentiation in prostate cancer: implications for
new treatment modalities. Eur Urol. 47:147–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng S, Agoulnik IU, Truong A, et al:
Suppression of relaxin receptor RXFP1 decreases prostate cancer
growth and metastasis. Endocr Relat Cancer. 17:1021–1033. 2010.
View Article : Google Scholar : PubMed/NCBI
|
